CLINICAL_TRIALS
trial_result
· 2009-08-13
Clinical Trial Update: Natalizumab High Titer Immunogenicity and Safety [Phase 2]
Summary
Phase 2 study of natalizumab in multiple sclerosis reports on high-titer immunogenicity and related safety findings. Results were posted in 2009.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Biogen | Conditions: Multiple Sclerosis | Phase 2 | Status: COMPLETED | Results posted: 2009-08-13